To ascertain whether topoisomerase inhibitors and 15d-PGJ2 synergistically exhibit the pharmacological effects on the VHL-negative ccRCC as well as the VHL-positive ccRCC, Caki-2 cells, 786-O cells were used as the VHL-negative ccRCC. Here, VHL is linked to nonpapillary renal cell carcinoma.